MetaCap

LENZ Therapeutics (LENZ) vs Voyager Therapeutics (VYGR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Voyager Therapeutics (VYGR) has outperformed LENZ Therapeutics (LENZ) over the past year, losing 63.4% versus a loss of 90.0%. Over five years, VYGR leads with a -50.0% price change compared with -95.6% for LENZ. Voyager Therapeutics is the larger company by market cap ($95.2 million vs $93.2 million), about 1.0 times the size.

Voyager Therapeutics converts more of its revenue into profit, with a net margin of -296.5% versus -430.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LENZ-89.97%VYGR-63.40%
+25%-35%-95%
Nov 21, 20251 yearNov 20, 2026
LENZ-96.18%VYGR-53.50%
+320%+102%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LENZ versus VYGR key metrics
MetricLENZVYGR
Share price$2.97$1.53
Market cap$93.16M$95.21M
1-day change-11.23%-4.97%
YTD return-81.47%-61.07%
1-year return-89.97%-63.40%
5-year return-95.57%-50.00%
EPS (TTM)$-4.53$-1.74
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$19.09M$40.37M
Revenue growth (YoY)—-49.53%
Net income (latest FY)$-82.13M$-119.72M
Gross margin97.81%—
Operating margin-477.46%-326.56%
Net margin-430.25%-296.53%
52-week high$32.13$5.48
52-week low$2.80$1.48
Distance from 52-week high-90.77%-72.08%
Analyst consensusnonestrong_buy
Avg. price target upside+400.17%+829.41%
Average volume892.30K770.24K
Shares outstanding31.42M62.23M
Employees40141
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VYGR has outperformed LENZ by 26.6 percentage points over the past year.
  • Voyager Therapeutics is more profitable, keeping -296.5 cents of every revenue dollar as net income versus -430.3 cents for LENZ Therapeutics.

About LENZ Therapeutics

LENZ stock →

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

About Voyager Therapeutics

VYGR stock →

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees

LENZ vs VYGR FAQ

Which is bigger, LENZ Therapeutics or Voyager Therapeutics?

Voyager Therapeutics (VYGR) is larger, with a market capitalization of $95.21M compared with $93.16M for LENZ Therapeutics (LENZ).

Which stock has performed better over the past year, LENZ or VYGR?

VYGR returned -63.40% over the past 12 months, compared with -89.97% for LENZ (price return, excluding dividends). Past performance does not predict future results.

Are LENZ Therapeutics and Voyager Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons